Shares of Viking Therapeutics (NASDAQ: VKTX) were up in pre-market trading at the time of publishing on Tuesday after the clinical-stage biopharmaceutical company announced positive top-line results from its Phase 2b clinical trial of VK2809. VK2809 is the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH), or non-alcoholic fatty liver disease.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
This trial successfully met the primary endpoint as patients receiving VK2809 experienced “statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.”
Analysts are bullish about VKTX stock with a Strong Buy consensus rating based on nine unanimous Buys.
